Teva to present data on Granix, Treanda, Trisenox injections at ASH meeting
Teva announced that data on GRANIX Injection, TREANDA Injection and TRISENOX Injection will be presented during poster sessions at the 2016 ASH Annual Meeting to be held at the San Diego Convention Center in San Diego, CA on December 3-6, 2016. Additional bendamustine abstracts were also accepted for publication in an online issue of Blood to be issued during the annual meeting. "We look forward to sharing real world data and outcomes research from our Oncology portfolio that provide deeper insights into our products," said Richard Nieman, M.D., SVP, Global Medical Affairs, Teva Pharmaceuticals. "The presentations at this year's ASH Meeting further highlight Teva's commitment to providing innovative medicines that positively impact our healthcare system, treatment and management of disease, and the lives of people, particularly those affected by cancer."